Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Wyszukujesz frazę ""BRCA2 Protein"" wg kryterium: Temat


Tytuł:
Exploiting replication gaps for cancer therapy.
Autorzy:
Cong K; Department of Molecular, Cell and Cancer Biology, University of Massachusetts Chan Medical School, Worcester, MA 01605, USA.
Cantor SB; Department of Molecular, Cell and Cancer Biology, University of Massachusetts Chan Medical School, Worcester, MA 01605, USA. Electronic address: .
Pokaż więcej
Źródło:
Molecular cell [Mol Cell] 2022 Jul 07; Vol. 82 (13), pp. 2363-2369. Date of Electronic Publication: 2022 May 13.
Typ publikacji:
Journal Article; Review; Research Support, N.I.H., Extramural
MeSH Terms:
BRCA1 Protein*/genetics
BRCA2 Protein*/genetics
DNA Breaks, Double-Stranded*
DNA Repair*/genetics
Neoplasms*/drug therapy
Neoplasms*/genetics
DNA ; Humans ; Poly(ADP-ribose) Polymerase Inhibitors/pharmacology ; Poly(ADP-ribose) Polymerase Inhibitors/therapeutic use
Czasopismo naukowe
Tytuł:
Chemotherapy Regimens Received by Women With BRCA1/2 Pathogenic Variants for Early Stage Breast Cancer Treatment.
Autorzy:
Kurian AW; Department of Medicine, Stanford University, Stanford, CA, USA.; Department of Epidemiology and Population Health, Stanford University, Stanford, CA, USA.
Abrahamse P; Department of Health Management and Policy, School of Public Health and Department of Internal Medicine, University of Michigan, Ann Arbor, MI, USA.
Hamilton AS; Department of Population and Public Health Sciences, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.
Caswell-Jin JL; Department of Medicine, Stanford University, Stanford, CA, USA.
Gomez SL; Department of Epidemiology & Biostatistics and Hellen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA, USA.
Hofer TJ; Department of Internal Medicine, University of Michigan and Center for Clinical Management Research, Veterans Affairs Ann Arbor Healthcare System, Ann Arbor, MI, USA.
Ward KC; Department of Epidemiology, Rollins School of Public Health, Emory University, Atlanta, GA, USA.
Katz SJ; Department of Health Management and Policy, School of Public Health and Department of Internal Medicine, University of Michigan, Ann Arbor, MI, USA.
Pokaż więcej
Źródło:
JNCI cancer spectrum [JNCI Cancer Spectr] 2022 Jul 01; Vol. 6 (4).
Typ publikacji:
Journal Article
MeSH Terms:
BRCA2 Protein*/genetics
Triple Negative Breast Neoplasms*/drug therapy
Anthracyclines/therapeutic use ; BRCA1 Protein/genetics ; Female ; Genetic Testing ; Humans ; Platinum/therapeutic use
Czasopismo naukowe
Tytuł:
Understanding and predicting the functional consequences of missense mutations in BRCA1 and BRCA2.
Autorzy:
Aljarf R; Computational Biology and Clinical Informatics, Baker Heart and Diabetes Institute, Melbourne, VIC, 3004, Australia.; Department of Biochemistry and Pharmacology, University of Melbourne, Melbourne, VIC, 3010, Australia.; Systems and Computational Biology, Bio21 Institute, University of Melbourne, 30 Flemington Rd, Parkville, VIC, 3052, Australia.
Shen M; Computational Biology and Clinical Informatics, Baker Heart and Diabetes Institute, Melbourne, VIC, 3004, Australia.; Department of Biochemistry and Pharmacology, University of Melbourne, Melbourne, VIC, 3010, Australia.; Systems and Computational Biology, Bio21 Institute, University of Melbourne, 30 Flemington Rd, Parkville, VIC, 3052, Australia.; School of Computing and Information Systems, University of Melbourne, Melbourne, VIC, 3053, Australia.
Pires DEV; Computational Biology and Clinical Informatics, Baker Heart and Diabetes Institute, Melbourne, VIC, 3004, Australia. .; Department of Biochemistry and Pharmacology, University of Melbourne, Melbourne, VIC, 3010, Australia. .; Systems and Computational Biology, Bio21 Institute, University of Melbourne, 30 Flemington Rd, Parkville, VIC, 3052, Australia. .; School of Computing and Information Systems, University of Melbourne, Melbourne, VIC, 3053, Australia. .
Ascher DB; Computational Biology and Clinical Informatics, Baker Heart and Diabetes Institute, Melbourne, VIC, 3004, Australia. .; Department of Biochemistry and Pharmacology, University of Melbourne, Melbourne, VIC, 3010, Australia. .; Systems and Computational Biology, Bio21 Institute, University of Melbourne, 30 Flemington Rd, Parkville, VIC, 3052, Australia. .; Department of Biochemistry, University of Cambridge, 80 Tennis Ct Rd, Cambridge, CB2 1GA, UK. .
Pokaż więcej
Źródło:
Scientific reports [Sci Rep] 2022 Jun 21; Vol. 12 (1), pp. 10458. Date of Electronic Publication: 2022 Jun 21.
Typ publikacji:
Journal Article
MeSH Terms:
BRCA1 Protein*/genetics
BRCA2 Protein*/genetics
Breast Neoplasms*/genetics
Mutation, Missense*
Ovarian Neoplasms*/genetics
Female ; Genes, BRCA2 ; Genetic Predisposition to Disease ; High-Throughput Nucleotide Sequencing ; Humans
Czasopismo naukowe
Tytuł:
Immunohistochemical Evaluation of BAP1 Expression in Breast Cancer with Known BRCA1 and BRCA2 Mutations and Comparison with Histopathological Features.
Autorzy:
Çalım-Gürbüz B; Pathology Department, Basaksehir Cam and Sakura City Hospital, Istanbul, Turkey.
Güvendir İ; Pathology Department, 147021Health Sciences University Umraniye Training and Research Hospital, Istanbul, Turkey.
Ünal B; Genomic Laboratory (GLAB), 147021Health Sciences University Umraniye Training and Research Hospital, Istanbul, Turkey.
Erdoğan-Durmuş Ş; Pathology Department, Basaksehir Cam and Sakura City Hospital, Istanbul, Turkey.
Topal CS; Pathology Department, 147021Health Sciences University Umraniye Training and Research Hospital, Istanbul, Turkey.
Ağaoğlu NB; Genomic Laboratory (GLAB), 147021Health Sciences University Umraniye Training and Research Hospital, Istanbul, Turkey.
Doğanay HL; Genomic Laboratory (GLAB), 147021Health Sciences University Umraniye Training and Research Hospital, Istanbul, Turkey.
Kızılboğa T; Genomic Laboratory (GLAB), 147021Health Sciences University Umraniye Training and Research Hospital, Istanbul, Turkey.
Zemheri IE; Pathology Department, 147021Health Sciences University Umraniye Training and Research Hospital, Istanbul, Turkey.
Pokaż więcej
Źródło:
International journal of surgical pathology [Int J Surg Pathol] 2022 Jun; Vol. 30 (4), pp. 397-404. Date of Electronic Publication: 2022 Mar 09.
Typ publikacji:
Journal Article
MeSH Terms:
BRCA1 Protein*/genetics
BRCA2 Protein*/genetics
Breast Neoplasms*/diagnosis
Breast Neoplasms*/genetics
Breast Neoplasms*/metabolism
Breast Neoplasms*/pathology
Tumor Suppressor Proteins*/genetics
Ubiquitin Thiolesterase*/genetics
Female ; Genes, BRCA2 ; Humans ; Mutation
Czasopismo naukowe
Tytuł:
DNA damage repair gene germline profiling for metastatic prostate cancer patients of different ancestries.
Autorzy:
Abdi B; Department of Medical Oncology, APHP, Tenon Hospital, Paris, France.
Basset N; Department of Genetics, Oncogenetics Consulting, Oncogenetics Functional Unit, Groupe Hospitalier Pitie-Salpetriere, APHP, Paris, France.
Perrot E; Department of Urology, CHU Pointe-a-Pitre/Abymes, Pointe a Pitre, Guadeloupe.
Benderra MA; Department of Medical Oncology, APHP, Tenon Hospital, Paris, France.
Khalil A; Department of Medical Oncology, APHP, Tenon Hospital, Paris, France.; GRC n°5 Predictive Onco-Urology, APHP, Tenon Hospital, Sorbonne Université, Paris, France.
Oudard S; Department of Medical Oncology, European Hospital Georges Pompidou, APHP, Paris, France.
Blanchet P; Department of Urology, CHU Pointe-a-Pitre/Abymes, Pointe a Pitre, Guadeloupe.
Brureau L; Department of Urology, CHU Pointe-a-Pitre/Abymes, Pointe a Pitre, Guadeloupe.
Coulet F; Department of Genetics, Oncogenetics Consulting, Oncogenetics Functional Unit, Groupe Hospitalier Pitie-Salpetriere, APHP, Paris, France.
Cussenot O; GRC n°5 Predictive Onco-Urology, APHP, Tenon Hospital, Sorbonne Université, Paris, France.; CeRePP, Paris, France.
Cancel-Tassin G; GRC n°5 Predictive Onco-Urology, APHP, Tenon Hospital, Sorbonne Université, Paris, France.; CeRePP, Paris, France.
Pokaż więcej
Źródło:
The Prostate [Prostate] 2022 Sep; Vol. 82 (12), pp. 1196-1201. Date of Electronic Publication: 2022 Jun 02.
Typ publikacji:
Journal Article
MeSH Terms:
BRCA2 Protein*/genetics
Prostatic Neoplasms*/genetics
Prostatic Neoplasms*/pathology
DNA Damage ; DNA Repair/genetics ; Genes, BRCA2 ; Germ Cells/pathology ; Germ-Line Mutation ; Humans ; Male
Czasopismo naukowe
Tytuł:
Homologous recombination deficiency in diverse cancer types and its correlation with platinum chemotherapy efficiency in ovarian cancer.
Autorzy:
Wen H; Department of Gynecologic Oncology, Fudan University Shanghai Cancer Center, 270 Dongan Road, Shanghai, 200032, China.; Department of Oncology, Shanghai Medical College, Fudan University, 130 Dongan Road, Shanghai, 200032, China.
Feng Z; Department of Gynecologic Oncology, Fudan University Shanghai Cancer Center, 270 Dongan Road, Shanghai, 200032, China.; Department of Oncology, Shanghai Medical College, Fudan University, 130 Dongan Road, Shanghai, 200032, China.
Ma Y; Geneseeq Research Institute, Nanjing Geneseeq Technology Inc, No. 128 Huakang Road, Pukou District, Nanjing, Jiangsu, 210000, China.
Liu R; Geneseeq Research Institute, Nanjing Geneseeq Technology Inc, No. 128 Huakang Road, Pukou District, Nanjing, Jiangsu, 210000, China.
Ou Q; Geneseeq Research Institute, Nanjing Geneseeq Technology Inc, No. 128 Huakang Road, Pukou District, Nanjing, Jiangsu, 210000, China.
Guo Q; Department of Gynecologic Oncology, Fudan University Shanghai Cancer Center, 270 Dongan Road, Shanghai, 200032, China.; Department of Oncology, Shanghai Medical College, Fudan University, 130 Dongan Road, Shanghai, 200032, China.
Shen Y; R&D, Nanjing Geneseeq Technology Inc, No. 128 Huakang Road, Pukou District, Nanjing, Jiangsu, 210000, China.
Wu X; Geneseeq Research Institute, Nanjing Geneseeq Technology Inc, No. 128 Huakang Road, Pukou District, Nanjing, Jiangsu, 210000, China.
Shao Y; Geneseeq Research Institute, Nanjing Geneseeq Technology Inc, No. 128 Huakang Road, Pukou District, Nanjing, Jiangsu, 210000, China.; School of Public Health, Nanjing Medical University, Jiangning District, 101 Longmian Avenue, Nanjing, Jiangsu, 211166, China.
Bao H; Geneseeq Research Institute, Nanjing Geneseeq Technology Inc, No. 128 Huakang Road, Pukou District, Nanjing, Jiangsu, 210000, China. .
Wu X; Department of Gynecologic Oncology, Fudan University Shanghai Cancer Center, 270 Dongan Road, Shanghai, 200032, China. .; Department of Oncology, Shanghai Medical College, Fudan University, 130 Dongan Road, Shanghai, 200032, China. .
Pokaż więcej
Źródło:
BMC cancer [BMC Cancer] 2022 May 16; Vol. 22 (1), pp. 550. Date of Electronic Publication: 2022 May 16.
Typ publikacji:
Journal Article
MeSH Terms:
BRCA2 Protein*/genetics
Ovarian Neoplasms*/drug therapy
Ovarian Neoplasms*/genetics
Ovarian Neoplasms*/pathology
Carcinoma, Ovarian Epithelial/genetics ; Female ; Homologous Recombination ; Humans ; Platinum/therapeutic use ; Recombinational DNA Repair/genetics
Czasopismo naukowe
Tytuł:
BRCA1/2 variants of unknown significance in hereditary breast and ovarian cancer (HBOC) syndrome: Looking for the hidden meaning.
Autorzy:
Fanale D; Section of Medical Oncology, Department of Surgical, Oncological and Oral Sciences, University of Palermo, 90127 Palermo, Italy.
Pivetti A; Section of Medical Oncology, Department of Surgical, Oncological and Oral Sciences, University of Palermo, 90127 Palermo, Italy.
Cancelliere D; Section of Medical Oncology, Department of Surgical, Oncological and Oral Sciences, University of Palermo, 90127 Palermo, Italy.
Spera A; Department of Radiotherapy, San Giovanni di Dio Hospital, ASP of Agrigento, Agrigento, Italy.
Bono M; Section of Medical Oncology, Department of Surgical, Oncological and Oral Sciences, University of Palermo, 90127 Palermo, Italy.
Fiorino A; Section of Medical Oncology, Department of Surgical, Oncological and Oral Sciences, University of Palermo, 90127 Palermo, Italy.
Pedone E; Section of Medical Oncology, Department of Surgical, Oncological and Oral Sciences, University of Palermo, 90127 Palermo, Italy.
Barraco N; Section of Medical Oncology, Department of Surgical, Oncological and Oral Sciences, University of Palermo, 90127 Palermo, Italy.
Brando C; Section of Medical Oncology, Department of Surgical, Oncological and Oral Sciences, University of Palermo, 90127 Palermo, Italy.
Perez A; Section of Medical Oncology, Department of Surgical, Oncological and Oral Sciences, University of Palermo, 90127 Palermo, Italy.
Guarneri MF; Azienda Sanitaria Provinciale of Palermo, Palermo, Italy.
Russo TDB; Section of Medical Oncology, Department of Surgical, Oncological and Oral Sciences, University of Palermo, 90127 Palermo, Italy.
Vieni S; Division of General and Oncological Surgery, Department of Surgical, Oncological and Oral Sciences, University of Palermo, Italy.
Guarneri G; Gynecology Section, Mother - Child Department, University of Palermo, 90127 Palermo, Italy.
Russo A; Section of Medical Oncology, Department of Surgical, Oncological and Oral Sciences, University of Palermo, 90127 Palermo, Italy. Electronic address: .
Bazan V; Department of Biomedicine, Neuroscience and Advanced Diagnostics, University of Palermo, 90127 Palermo, Italy.
Pokaż więcej
Źródło:
Critical reviews in oncology/hematology [Crit Rev Oncol Hematol] 2022 Apr; Vol. 172, pp. 103626. Date of Electronic Publication: 2022 Feb 10.
Typ publikacji:
Journal Article; Review
MeSH Terms:
BRCA1 Protein*/genetics
BRCA2 Protein*/genetics
Breast Neoplasms*/genetics
Hereditary Breast and Ovarian Cancer Syndrome*/diagnosis
Hereditary Breast and Ovarian Cancer Syndrome*/genetics
Ovarian Neoplasms*/genetics
Female ; Genetic Predisposition to Disease ; Germ-Line Mutation ; Humans ; Mutation ; Risk Assessment
Czasopismo naukowe
Tytuł:
Prevalence of BRCA1 and BRCA2 Germline Mutations in Patients of African Descent with Early-Onset and Familial Colombian Breast Cancer.
Autorzy:
Vargas E; Institute of Human Genetics, Pontificia Universidad Javeriana, Bogota, Colombia.; Molecular Genetics of Breast Cancer, German Cancer Research Center (DKFZ), Heidelberg, Germany.
de Deugd R; CENTOGENE GmbH, Rostock, Germany.
Villegas VE; Centro de Investigaciones en Microbiología y Biotecnología-UR (CIMBIUR), Facultad de Ciencias Naturales, Universidad del Rosario, Bogota, Colombia.
Gil F; Unit of Clinical Epidemiology and Biostatistics, Pontificia Universidad Javeriana, Bogota, Colombia.
Mora L; Institute of Human Genetics, Pontificia Universidad Javeriana, Bogota, Colombia.
Viaña LF; Cancer League, Cartagena, Colombia.
Bruges R; Centro Javeriano de Oncología, Pontificia Universidad Javeriana, Bogota, Colombia.
Gonzalez A; Centro Javeriano de Oncología, Pontificia Universidad Javeriana, Bogota, Colombia.
Galvis JC; Centro Javeriano de Oncología, Pontificia Universidad Javeriana, Bogota, Colombia.
Hamann U; Molecular Genetics of Breast Cancer, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Torres D; Institute of Human Genetics, Pontificia Universidad Javeriana, Bogota, Colombia.; Molecular Genetics of Breast Cancer, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Pokaż więcej
Źródło:
The oncologist [Oncologist] 2022 Mar 04; Vol. 27 (2), pp. e151-e157.
Typ publikacji:
Journal Article
MeSH Terms:
BRCA1 Protein*/genetics
BRCA2 Protein*/genetics
Breast Neoplasms*/epidemiology
Breast Neoplasms*/genetics
Germ-Line Mutation*
Colombia/epidemiology ; Female ; Humans ; Prevalence
SCR Disease Name:
Breast Cancer, Familial
Czasopismo naukowe
Tytuł:
BRCA mutations: Implications of genetic testing in ovarian cancer.
Autorzy:
Talwar V; Department of Medical Oncology, Rajiv Gandhi Cancer Institute, Rohini, New Delhi, India.
Rauthan A; Consultant Medical Oncology, Manipal Hospitals, Bengaluru, Karnataka, India.
Pokaż więcej
Źródło:
Indian journal of cancer [Indian J Cancer] 2022 Mar; Vol. 59 (Supplement), pp. S56-S67.
Typ publikacji:
Journal Article; Review
MeSH Terms:
BRCA1 Protein*/genetics
BRCA2 Protein*/genetics
Genes, BRCA1*
Ovarian Neoplasms*/diagnosis
Ovarian Neoplasms*/genetics
Carcinoma, Ovarian Epithelial/genetics ; Female ; Genetic Testing/methods ; Humans ; Mutation
Czasopismo naukowe
Tytuł:
Loss of MED12 activates the TGFβ pathway to promote chemoresistance and replication fork stability in BRCA-deficient cells.
Autorzy:
Jackson LM; Department of Biochemistry and Molecular Biology, The Pennsylvania State University College of Medicine, Hershey, PA 17033, USA.
Dhoonmoon A; Department of Biochemistry and Molecular Biology, The Pennsylvania State University College of Medicine, Hershey, PA 17033, USA.
Hale A; Department of Biochemistry and Molecular Biology, The Pennsylvania State University College of Medicine, Hershey, PA 17033, USA.
Dennis KA; Department of Biochemistry and Molecular Biology, The Pennsylvania State University College of Medicine, Hershey, PA 17033, USA.
Schleicher EM; Department of Biochemistry and Molecular Biology, The Pennsylvania State University College of Medicine, Hershey, PA 17033, USA.
Nicolae CM; Department of Biochemistry and Molecular Biology, The Pennsylvania State University College of Medicine, Hershey, PA 17033, USA.
Moldovan GL; Department of Biochemistry and Molecular Biology, The Pennsylvania State University College of Medicine, Hershey, PA 17033, USA.
Pokaż więcej
Źródło:
Nucleic acids research [Nucleic Acids Res] 2021 Dec 16; Vol. 49 (22), pp. 12855-12869.
Typ publikacji:
Journal Article; Research Support, N.I.H., Extramural
MeSH Terms:
BRCA1 Protein/*genetics
BRCA2 Protein/*genetics
DNA Replication/*genetics
Drug Resistance, Neoplasm/*genetics
Mediator Complex/*genetics
Transforming Growth Factor beta/*genetics
Antineoplastic Agents/pharmacology ; BRCA1 Protein/deficiency ; BRCA1 Protein/metabolism ; BRCA2 Protein/deficiency ; BRCA2 Protein/metabolism ; Cell Line ; Cell Line, Tumor ; Cell Survival/drug effects ; Cell Survival/genetics ; Cisplatin/pharmacology ; DNA/chemistry ; DNA/genetics ; DNA/metabolism ; DNA Repair ; HeLa Cells ; Humans ; Mediator Complex/metabolism ; Phthalazines/pharmacology ; Piperazines/pharmacology ; Poly(ADP-ribose) Polymerase Inhibitors/pharmacology ; RNA Interference ; Signal Transduction/genetics ; Transforming Growth Factor beta/metabolism
Czasopismo naukowe
Tytuł:
Cockayne syndrome group B protein regulates fork restart, fork progression and MRE11-dependent fork degradation in BRCA1/2-deficient cells.
Autorzy:
Batenburg NL; Department of Biology, McMaster University, Hamilton, Ontario L8S 4K1, Canada.
Mersaoui SY; CHU de Québec-Université Laval, Oncology Division, Department of Molecular Biology, Medical Biochemistry and Pathology, Laval University Cancer Research Center, 9 McMahon, Québec City, Québec G1R 3S3, Canada.
Walker JR; Department of Biology, McMaster University, Hamilton, Ontario L8S 4K1, Canada.
Coulombe Y; CHU de Québec-Université Laval, Oncology Division, Department of Molecular Biology, Medical Biochemistry and Pathology, Laval University Cancer Research Center, 9 McMahon, Québec City, Québec G1R 3S3, Canada.
Hammond-Martel I; Centre de recherche, de l'Hôpital Maisonneuve-Rosemont, 5415 boulevard de l'Assomption, Montréal, Québec H1T 2M4, Canada.
Wurtele H; Centre de recherche, de l'Hôpital Maisonneuve-Rosemont, 5415 boulevard de l'Assomption, Montréal, Québec H1T 2M4, Canada.; Department of Medicine, Université de Montréal, Montréal, Québec H3T 1J4, Canada.
Masson JY; CHU de Québec-Université Laval, Oncology Division, Department of Molecular Biology, Medical Biochemistry and Pathology, Laval University Cancer Research Center, 9 McMahon, Québec City, Québec G1R 3S3, Canada.
Zhu XD; Department of Biology, McMaster University, Hamilton, Ontario L8S 4K1, Canada.
Pokaż więcej
Źródło:
Nucleic acids research [Nucleic Acids Res] 2021 Dec 16; Vol. 49 (22), pp. 12836-12854.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
DNA Repair*
BRCA1 Protein/*genetics
BRCA2 Protein/*genetics
DNA/*genetics
DNA Helicases/*genetics
DNA Repair Enzymes/*genetics
MRE11 Homologue Protein/*genetics
Poly-ADP-Ribose Binding Proteins/*genetics
BRCA1 Protein/deficiency ; BRCA1 Protein/metabolism ; BRCA2 Protein/deficiency ; BRCA2 Protein/metabolism ; Cell Line ; Cell Line, Tumor ; DNA/chemistry ; DNA/metabolism ; DNA Breaks, Double-Stranded ; DNA Helicases/metabolism ; DNA Repair Enzymes/metabolism ; DNA Replication/genetics ; HCT116 Cells ; HEK293 Cells ; Humans ; MRE11 Homologue Protein/metabolism ; Mutation ; Poly-ADP-Ribose Binding Proteins/metabolism ; RNA Interference
Czasopismo naukowe
Tytuł:
Evaluation of two evidence-based decision aids for female BRCA1/2 mutation carriers in Germany: study protocol for a randomised controlled parallel-group trial.
Autorzy:
Kautz-Freimuth S; Institute of Health Economics and Clinical Epidemiology, The University Hospital of Cologne, Gleueler Straße 176-178, 50935, Cologne, Germany. .
Redaèlli M; Institute of Health Economics and Clinical Epidemiology, The University Hospital of Cologne, Gleueler Straße 176-178, 50935, Cologne, Germany.
Isselhard A; Institute of Health Economics and Clinical Epidemiology, The University Hospital of Cologne, Gleueler Straße 176-178, 50935, Cologne, Germany.
Shukri A; Institute of Health Economics and Clinical Epidemiology, The University Hospital of Cologne, Gleueler Straße 176-178, 50935, Cologne, Germany.
Vodermaier A; Institute of Health Economics and Clinical Epidemiology, The University Hospital of Cologne, Gleueler Straße 176-178, 50935, Cologne, Germany.; School of Population and Public Health, The University of British Columbia, 2206 East Mall, Vancouver, BC, C6T 1Z3, Canada.
Rhiem K; Centre for Familial Breast and Ovarian Cancer, Centre for Integrated Oncology (CIO), Faculty of Medicine and The University Hospital of Cologne, University of Cologne, Kerpener Straße 62, 50937, Cologne, Germany.
Schmutzler R; Centre for Familial Breast and Ovarian Cancer, Centre for Integrated Oncology (CIO), Faculty of Medicine and The University Hospital of Cologne, University of Cologne, Kerpener Straße 62, 50937, Cologne, Germany.
Stock S; Institute of Health Economics and Clinical Epidemiology, The University Hospital of Cologne, Gleueler Straße 176-178, 50935, Cologne, Germany.
Pokaż więcej
Źródło:
Trials [Trials] 2022 Feb 16; Vol. 23 (1), pp. 157. Date of Electronic Publication: 2022 Feb 16.
Typ publikacji:
Clinical Trial Protocol; Journal Article
MeSH Terms:
BRCA1 Protein*/genetics
BRCA2 Protein*/genetics
Breast Neoplasms*/genetics
Breast Neoplasms*/prevention & control
Ovarian Neoplasms*/genetics
Ovarian Neoplasms*/prevention & control
Decision Support Techniques ; Female ; Germany ; Humans ; Mastectomy ; Mutation ; Randomized Controlled Trials as Topic
Czasopismo naukowe
Tytuł:
Single-cell tumor-immune microenvironment of BRCA1/2 mutated high-grade serous ovarian cancer.
Autorzy:
Launonen IM; Research Program in Systems Oncology, University of Helsinki, Helsinki, Finland.
Lyytikäinen N; Research Program in Systems Oncology, University of Helsinki, Helsinki, Finland.
Casado J; Research Program in Systems Oncology, University of Helsinki, Helsinki, Finland.
Anttila EA; Research Program in Systems Oncology, University of Helsinki, Helsinki, Finland.
Szabó A; Research Program in Systems Oncology, University of Helsinki, Helsinki, Finland.
Haltia UM; Research Program in Systems Oncology, University of Helsinki, Helsinki, Finland.; Department of Obstetrics and Gynecology, Helsinki University Hospital, Helsinki, Finland.
Jacobson CA; Laboratory of Systems Pharmacology, Harvard Medical School, Boston, MA, USA.
Lin JR; Laboratory of Systems Pharmacology, Harvard Medical School, Boston, MA, USA.
Maliga Z; Laboratory of Systems Pharmacology, Harvard Medical School, Boston, MA, USA.
Howitt BE; Department of Pathology, Stanford University School of Medicine, Stanford, CA, USA.
Strickland KC; Department of Pathology, Duke University Medical Center, Durham, NC, USA.
Santagata S; Laboratory of Systems Pharmacology, Harvard Medical School, Boston, MA, USA.; Department of Pathology, Brigham and Women's Hospital, Boston, MA, USA.; Ludwig Center for Cancer Research at Harvard, Harvard Medical School, Boston, MA, USA.
Elias K; Department of Obstetrics and Gynecology and Reproductive Biology, Brigham and Women's Hospital, Boston, MA, USA.; Dana-Farber Cancer Institute, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
D'Andrea AD; Dana-Farber Cancer Institute, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Konstantinopoulos PA; Dana-Farber Cancer Institute, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Sorger PK; Laboratory of Systems Pharmacology, Harvard Medical School, Boston, MA, USA.; Ludwig Center for Cancer Research at Harvard, Harvard Medical School, Boston, MA, USA.
Färkkilä A; Research Program in Systems Oncology, University of Helsinki, Helsinki, Finland. .; Department of Obstetrics and Gynecology, Helsinki University Hospital, Helsinki, Finland. .; Laboratory of Systems Pharmacology, Harvard Medical School, Boston, MA, USA. .; Dana-Farber Cancer Institute, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA. .; iCAN Digital Precision Cancer Medicine Flagship, Helsinki, Finland. .
Pokaż więcej
Źródło:
Nature communications [Nat Commun] 2022 Feb 11; Vol. 13 (1), pp. 835. Date of Electronic Publication: 2022 Feb 11.
Typ publikacji:
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
MeSH Terms:
BRCA1 Protein/*metabolism
BRCA2 Protein/*metabolism
Carcinoma, Ovarian Epithelial/*immunology
Cystadenocarcinoma, Serous/*immunology
Ovarian Neoplasms/*immunology
Tumor Microenvironment/*immunology
BRCA1 Protein/genetics ; BRCA2 Protein/genetics ; CD4-Positive T-Lymphocytes ; CD8-Positive T-Lymphocytes ; Carcinoma, Ovarian Epithelial/genetics ; Cystadenocarcinoma, Serous/genetics ; Female ; Genes, BRCA1 ; Genes, BRCA2 ; Genotype ; Homologous Recombination ; Humans ; Mutation ; Ovarian Neoplasms/genetics ; Prognosis ; Proteomics
Czasopismo naukowe
Tytuł:
Frequency of germline BRCA1/2 mutations and association with clinicopathological characteristics in Turkish women with epithelial ovarian cancer.
Autorzy:
Sunar V; Department of Medical Oncology, Zekai Tahir Burak Women's Health Research and Education Hospital, Faculty of Medicine, University of Health Sciences, Ankara, Turkey.
Korkmaz V; Department of Gynecologic Oncology, Zekai Tahir Burak Women's Health Research and Education Hospital, Faculty of Medicine, University of Health Sciences, Ankara, Turkey.
Topcu V; Department of Medical Genetics, Zekai Tahir Burak Women's Health Research and Education Hospital, Faculty of Medicine, University of Health Sciences, Ankara, Turkey.
Cavdarli B; Department of Medical Genetics, Ankara Numune Training and Research Hospital, Faculty of Medicine, University of Health Sciences, Ankara, Turkey.
Arik Z; Department of Medical Oncology, Hacettepe University Cancer Institute, Ankara, Turkey.
Ozdal B; Department of Gynecologic Oncology, Zekai Tahir Burak Women's Health Research and Education Hospital, Faculty of Medicine, University of Health Sciences, Ankara, Turkey.
Ustun YE; Department of Gynecology and Obstetrics, Zekai Tahir Burak Women's Health Research and Education Hospital, Faculty of Medicine, University of Health Sciences, Ankara, Turkey.
Pokaż więcej
Źródło:
Asia-Pacific journal of clinical oncology [Asia Pac J Clin Oncol] 2022 Feb; Vol. 18 (1), pp. 84-92. Date of Electronic Publication: 2021 Feb 25.
Typ publikacji:
Journal Article
MeSH Terms:
BRCA1 Protein*/genetics
BRCA2 Protein*/genetics
Carcinoma, Ovarian Epithelial*/genetics
Germ-Line Mutation*
Ovarian Neoplasms*/genetics
Breast Neoplasms ; Cross-Sectional Studies ; Female ; Genetic Predisposition to Disease ; Germ Cells ; Humans ; Mutation
Czasopismo naukowe
Tytuł:
Evaluation of the indication of BRCA1/2 genetic tests in Iranian women and acceptance rate of risk-reducing surgeries in BRCA mutation carriers.
Autorzy:
Vasigh M; Breast Disease Research Center, Cancer Institute,Tehran University of Medical Sciences, Tehran, Iran.
Eslami B; Breast Disease Research Center, Cancer Institute,Tehran University of Medical Sciences, Tehran, Iran.
Elahi A; Department of Surgery, Alborz University of Medical Sciences, Karaj, Iran.
Kaviani A; Breast Disease Research Center, Cancer Institute,Tehran University of Medical Sciences, Tehran, Iran.; Department of Surgery, Tehran University of Medical Sciences, Tehran, Iran.; Department of Surgical Oncology, University de Montreal, Montreal, Canada.
Shirkoohi R; Department of Molecular Genetics, Cancer Research Center, Cancer Institute, Tehran University of Medical Sciences, Tehran, Iran.
Majidzadeh K; Breast Cancer Research Center, Motamed Cancer Institute, ACECR, Tehran, Iran.
Nazarian N; Tehran Medical Sciences Branch, Islamic Azad University, Tehran, Iran.
Omranipour R; Breast Disease Research Center, Cancer Institute,Tehran University of Medical Sciences, Tehran, Iran.; Department of Surgical Oncology, Cancer Institute, Tehran University of Medical Sciences, Tehran, Iran.
Pokaż więcej
Źródło:
Molecular genetics & genomic medicine [Mol Genet Genomic Med] 2022 Feb; Vol. 10 (2), pp. e1867. Date of Electronic Publication: 2022 Jan 12.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
BRCA1 Protein*/genetics
BRCA2 Protein*/genetics
Breast Neoplasms*/epidemiology
Breast Neoplasms*/genetics
Breast Neoplasms*/surgery
Adult ; Female ; Genetic Testing ; Humans ; Iran ; Mastectomy ; Middle Aged ; Mutation ; Retrospective Studies
Czasopismo naukowe
Tytuł:
The BRCA2 missense mutation K2497R suppressed self-degradation and increased ATP production and cell proliferation.
Autorzy:
Enkhbat G; Department of Specialized Surgeries, Tokyo Medical and Dental University, 1-5-45 Yushima, Bunkyo-ku, Tokyo, 113-8510, Japan; Department of Molecular Genetics, Medical Research Institute, Tokyo Medical and Dental University, 1-5-45 Yushima, Bunkyo-ku, Tokyo, 113-8510, Japan.
Nakanishi A; Department of Molecular Genetics, Medical Research Institute, Tokyo Medical and Dental University, 1-5-45 Yushima, Bunkyo-ku, Tokyo, 113-8510, Japan. Electronic address: .
Miki Y; Department of Molecular Genetics, Medical Research Institute, Tokyo Medical and Dental University, 1-5-45 Yushima, Bunkyo-ku, Tokyo, 113-8510, Japan; Department of Genetic Diagnosis, The Cancer Institute, Japanese Foundation for Cancer Research, 3-8-31 Ariake, Koto-ku, Tokyo, 135-8550, Japan. Electronic address: .
Pokaż więcej
Źródło:
Biochemical and biophysical research communications [Biochem Biophys Res Commun] 2022 Jan 29; Vol. 590, pp. 27-33. Date of Electronic Publication: 2021 Dec 23.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Proteolysis*
Adenosine Triphosphate/*biosynthesis
BRCA2 Protein/*genetics
Mutation, Missense/*genetics
Amino Acid Sequence ; BRCA2 Protein/chemistry ; Breast Neoplasms/genetics ; Breast Neoplasms/pathology ; Cell Line, Tumor ; Cell Proliferation/genetics ; Female ; HEK293 Cells ; HSP27 Heat-Shock Proteins/metabolism ; Humans ; Lysine/genetics ; Peptides/chemistry ; Peptides/metabolism ; Protein Binding ; Ubiquitin/metabolism ; Ubiquitination
SCR Disease Name:
Breast Cancer, Familial
Czasopismo naukowe
Tytuł:
BRCA2 represses the transcriptional activity of pS2 by E2-ERα.
Autorzy:
Fukuda M; Department of Specialized Surgeries, Tokyo Medical and Dental University (TMDU), 1-5-45 Yushima, Bunkyo-ku, Tokyo, 113-8510, Japan.
Tojo Y; Department of Molecular Genetics, Medical Research Institute, Tokyo Medical and Dental University (TMDU), 1-5-45 Yushima, Bunkyo-ku, Tokyo, 113-8510, Japan.
Sato A; Department of Molecular Genetics, Medical Research Institute, Tokyo Medical and Dental University (TMDU), 1-5-45 Yushima, Bunkyo-ku, Tokyo, 113-8510, Japan.
Saito H; Department of Genetic Diagnosis, The Cancer Institute, Japanese Foundation for Cancer Research, 3-8-31 Ariake, Koto-ku, Tokyo, 135-8550, Japan.
Nakanishi A; Department of Molecular Genetics, Medical Research Institute, Tokyo Medical and Dental University (TMDU), 1-5-45 Yushima, Bunkyo-ku, Tokyo, 113-8510, Japan. Electronic address: .
Miki Y; Department of Molecular Genetics, Medical Research Institute, Tokyo Medical and Dental University (TMDU), 1-5-45 Yushima, Bunkyo-ku, Tokyo, 113-8510, Japan; Department of Genetic Diagnosis, The Cancer Institute, Japanese Foundation for Cancer Research, 3-8-31 Ariake, Koto-ku, Tokyo, 135-8550, Japan. Electronic address: .
Pokaż więcej
Źródło:
Biochemical and biophysical research communications [Biochem Biophys Res Commun] 2022 Jan 15; Vol. 588, pp. 75-82. Date of Electronic Publication: 2021 Dec 20.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Transcription, Genetic*
BRCA2 Protein/*metabolism
Estradiol/*metabolism
Estrogen Receptor alpha/*metabolism
Proteins/*genetics
Trefoil Factor-1/*genetics
BRCA2 Protein/chemistry ; Gene Expression Regulation, Neoplastic ; Humans ; MCF-7 Cells ; Nuclear Receptor Coactivator 1/metabolism ; Promoter Regions, Genetic ; Protein Binding ; Protein Domains ; Proteins/metabolism ; Transcription Factors/metabolism ; Trefoil Factor-1/metabolism
Czasopismo naukowe
Tytuł:
Concordance of BRCA mutation detection in tumor versus blood, and frequency of bi-allelic loss of BRCA in tumors from patients in the phase III SOLO2 trial.
Autorzy:
Hodgson DR; Translational Medicine, Oncology R+D, Research and Early Development, AstraZeneca, Boston, MA, USA.
Brown JS; Translational Medicine, Oncology R+D, Research and Early Development, AstraZeneca, Cambridge, United Kingdom. Electronic address: .
Dearden SP; Precision Medicine and Biosamples, R&D Oncology, AstraZeneca, Cambridge, United Kingdom.
Lai Z; Translational Medicine, Oncology R+D, Research and Early Development, AstraZeneca, Boston, MA, USA.
Elks CE; Precision Medicine and Biosamples, R&D Oncology, AstraZeneca, Cambridge, United Kingdom.
Milenkova T; AstraZeneca, Cambridge, United Kingdom.
Dougherty BA; Translational Medicine, Oncology R+D, Research and Early Development, AstraZeneca, Boston, MA, USA.
Lanchbury JS; Myriad Genetics, Salt Lake City, UT, USA.
Perry M; Myriad Genetics, Salt Lake City, UT, USA.
Timms KM; Myriad Genetics, Salt Lake City, UT, USA.
Harrington EA; Translational Medicine, Oncology R+D, Research and Early Development, AstraZeneca, Cambridge, United Kingdom.
Barrett JC; Translational Medicine, Oncology R+D, Research and Early Development, AstraZeneca, Boston, MA, USA.
Leary A; Department of Medicine and INSERM U981, Université Paris Saclay and Institut Gustave-Roussy, Villejuif, France.
Pujade-Lauraine E; Medical Oncology Department, Université Paris Descartes, AP-HP, Paris, France.
Pokaż więcej
Źródło:
Gynecologic oncology [Gynecol Oncol] 2021 Dec; Vol. 163 (3), pp. 563-568. Date of Electronic Publication: 2021 Nov 04.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Germ-Line Mutation*
Loss of Heterozygosity*
BRCA2 Protein/*genetics
Ovarian Neoplasms/*genetics
Ubiquitin-Protein Ligases/*genetics
Antineoplastic Agents/therapeutic use ; BRCA2 Protein/blood ; Carcinoma, Endometrioid/blood ; Carcinoma, Endometrioid/genetics ; Clinical Trials, Phase III as Topic ; Fallopian Tube Neoplasms/blood ; Fallopian Tube Neoplasms/genetics ; Female ; Humans ; Ovarian Neoplasms/blood ; Peritoneal Neoplasms/blood ; Peritoneal Neoplasms/genetics ; Phthalazines/therapeutic use ; Piperazines/therapeutic use ; Polymorphism, Single Nucleotide ; Randomized Controlled Trials as Topic ; Ubiquitin-Protein Ligases/blood
Czasopismo naukowe
Tytuł:
Vaginal NOTES approach for risk-reducing salpingo-oophorectomy in BRCA mutation carriers: A video demonstration.
Autorzy:
Netter A; Department of Gynecology and Obstetrics, La Conception Hospital, Aix Marseille University, Marseille, France; Institut Méditerranéen de Biodiversité et d'Écologie marine et continentale (IMBE), Aix Marseille University, CNRS, IRD, Avignon University, Marseille, France.
Niddam R; Department of Gynecology and Obstetrics, La Conception Hospital, Aix Marseille University, Marseille, France.
Agostini A; Department of Gynecology and Obstetrics, La Conception Hospital, Aix Marseille University, Marseille, France.
Crochet P; Department of Gynecology and Obstetrics, La Conception Hospital, Aix Marseille University, Marseille, France. Electronic address: '.
Pokaż więcej
Źródło:
Journal of gynecology obstetrics and human reproduction [J Gynecol Obstet Hum Reprod] 2021 Dec; Vol. 50 (10), pp. 102212. Date of Electronic Publication: 2021 Sep 02.
Typ publikacji:
Case Reports; Journal Article
MeSH Terms:
BRCA1 Protein/*analysis
BRCA2 Protein/*analysis
Salpingo-oophorectomy/*standards
BRCA1 Protein/genetics ; BRCA2 Protein/genetics ; Female ; Heterozygote ; Humans ; Middle Aged ; Risk Reduction Behavior ; Salpingo-oophorectomy/methods ; Salpingo-oophorectomy/statistics & numerical data
Czasopismo naukowe
Tytuł:
BRCA2 associates with MCM10 to suppress PRIMPOL-mediated repriming and single-stranded gap formation after DNA damage.
Autorzy:
Kang Z; Department of Radiation Oncology, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA.
Fu P; Department of Radiation Oncology, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA.; Department of Clinical Microbiology Laboratory, Children's Hospital of Fudan University, Shanghai, China.
Alcivar AL; Department of Radiation Oncology, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA.; Bristol-Myers Squibb Company, Bloomsbury, NJ, 08804, USA.
Fu H; Developmental Therapeutics Group, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA.
Redon C; Developmental Therapeutics Group, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA.
Foo TK; Department of Radiation Oncology, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA.
Zuo Y; Department of Radiation Oncology, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA.
Ye C; Department of Radiation Oncology, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA.; School of Radiation Medicine and Protection, Soochow University, Suzhou, China.
Baxley R; Department of Biochemistry, Molecular Biology, and Biophysics, University of Minnesota, Minneapolis, MN, USA.
Madireddy A; Department of Pediatric Hematology/Oncology, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA.
Buisson R; Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, MA, USA.; Department of Biological Chemistry, University of California Irvine, Irvine, CA, USA.
Bielinsky AK; Department of Biochemistry, Molecular Biology, and Biophysics, University of Minnesota, Minneapolis, MN, USA.
Zou L; Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, MA, USA.
Shen Z; Department of Radiation Oncology, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA.
Aladjem MI; Developmental Therapeutics Group, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA.
Xia B; Department of Radiation Oncology, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA. .
Pokaż więcej
Źródło:
Nature communications [Nat Commun] 2021 Oct 13; Vol. 12 (1), pp. 5966. Date of Electronic Publication: 2021 Oct 13.
Typ publikacji:
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
MeSH Terms:
Recombinational DNA Repair*
BRCA2 Protein/*genetics
DNA Primase/*genetics
DNA, Neoplasm/*genetics
DNA, Single-Stranded/*genetics
DNA-Directed DNA Polymerase/*genetics
Minichromosome Maintenance Proteins/*genetics
Multifunctional Enzymes/*genetics
BRCA2 Protein/antagonists & inhibitors ; BRCA2 Protein/metabolism ; Cell Line, Tumor ; Cell Survival ; DNA Damage ; DNA Helicases/antagonists & inhibitors ; DNA Helicases/genetics ; DNA Helicases/metabolism ; DNA Primase/antagonists & inhibitors ; DNA Primase/metabolism ; DNA Replication ; DNA, Neoplasm/metabolism ; DNA, Single-Stranded/metabolism ; DNA-Binding Proteins/antagonists & inhibitors ; DNA-Binding Proteins/genetics ; DNA-Binding Proteins/metabolism ; DNA-Directed DNA Polymerase/metabolism ; Gene Expression Regulation, Neoplastic ; Genomic Instability ; HEK293 Cells ; HeLa Cells ; Humans ; Minichromosome Maintenance Proteins/antagonists & inhibitors ; Minichromosome Maintenance Proteins/metabolism ; Multifunctional Enzymes/antagonists & inhibitors ; Multifunctional Enzymes/metabolism ; Osteoblasts/metabolism ; Osteoblasts/pathology ; RNA, Small Interfering/genetics ; RNA, Small Interfering/metabolism ; Signal Transduction ; Transcription Factors/antagonists & inhibitors ; Transcription Factors/genetics ; Transcription Factors/metabolism
Czasopismo naukowe

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies

Prześlij opinię

Twoje opinie są dla nas bardzo ważne i mogą być niezwykle pomocne w pokazaniu nam, gdzie możemy dokonać ulepszeń. Bylibyśmy bardzo wdzięczni za poświęcenie kilku chwil na wypełnienie krótkiego formularza.

Formularz